sources: Facebook
– The future of health and wellness is becoming more personalized and informed by data. By combining Bioniq’s personalized supplement technology with Pro2col and the power of our global distributor network, we are expanding our ability to deliver personalized wellness at global scale – said Herbalife chief executive officer, Stephan Gratziani.
Bioniq develops personalized supplement formulas using its patented product personalization engine, an individual’s health background, and a proprietary database of biomarkers. Bioniq’s personalized supplement formulations are designed for a broad range of individuals, from everyday wellness consumers to elite athletes, including Cristiano Ronaldo.
Bioniq will complement Herbalife’s prior acquisitions of Pro2col and Link BioSciences by enabling Herbalife to offer a broader range of personalized nutritional supplements across multiple delivery formats. Combining Bioniq’s offering with Herbalife’s global manufacturing expertise will enable the company to expand personalized nutrition at scale and speed.
– I founded Bioniq in 2019 with a vision to help people optimize their wellbeing through a science-driven approach to nutrition that incorporates biomarker and lifestyle data. I am excited to join Herbalife with its global distributor network and commitment to advancing wellness at scale – said Vadim Fedotov, founder and president of Bioniq.
As a long-time global nutrition partner of Herbalife and Bioniq shareholder, Cristiano Ronaldo shares Herbalife’s vision to accelerate the availability of personalized nutritional supplements at scale through its global distributor network.
– Throughout my career, biometrics and personalized nutrition have been central to helping me perform and compete at the highest level. As a long-time Herbalife and Bioniq user, I’ve experienced firsthand how a tailored approach to nutrition can help optimize performance – said Cristiano Ronaldo.
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory approvals. The $55 million purchase price will be paid over five years, including an initial payment of $10 million at closing. In addition, the transaction value includes up to $95 million of contingent payments based on future performance.
As part of the transaction, Herbalife also obtained a call option to acquire Bioniq LAB, a separate platform focused on small molecules and peptides. The call option provides Herbalife with strategic flexibility to evaluate potential longer-term opportunities in this area in a disciplined and capital-efficient manner.
